Clinical Trial Update: A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating sintilimab in combination with R-CHOP for primary mediastinal large B-cell lymphoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Primary Mediastinal Large B Cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING